Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19

SOUTH SAN FRANCISCO, Calif., April 13, 2021 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized patients with COVID-19. The trial, being conducted in collaboration with the…

Read the full article here

Source: Rigel Pharmaceuticals, Inc.

Categories: Latest Headlines, Rheumatology

Tags: covid19

Tweets with this article

Dr Taryn Youngstein 💙

Fostamatinib: Ruxolitinib: SoC in COVID-19 patients from admission. @imperialcollege @ImperialNHS study now multi-site @ImperialBRC @ImperialImmuno Plus @RigelPharma +ve top line data on primary safety end point with Fostamatinib in COVID-19 https://t.co/rrq4Frr2AK https://t.co/VLQ3Vcd01i

The Tour 21 – JustGiving

The Tour 21 will see a team of amateur cyclists ride all 21 stages of the 2023 Tour de France, one week ahead of the…

Dr Taryn Youngstein July 16, 2023

In memory of Professor Justin Mason

Help National Heart and Lung Institute NHLI raise money to support Imperial College

Dr Taryn Youngstein July 4, 2022

Thanksgiving Service for Professor Justin Mason

A Thanksgiving Service to celebrate the life of Professor Justin Mason will be held at St Luke’s Church on Thursday 22 September 2022…

Dr Taryn Youngstein July 4, 2022

The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic – PubMed

Coronavirus disease 2019 (COVID-19) was first identified in December 2019 in Wuhan, China. The first analyses of cases described high numbers of critically ill patients…

Dr Taryn Youngstein April 29, 2022

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day…

Dr Taryn Youngstein April 24, 2022

VROOM home page | VROOM

Welcome to the VROOM study website! Full study title: A multi-centre randomised controlled trial examining the effects of temporarily suspending low-dose methotrexate treatment for two…

Dr Taryn Youngstein November 29, 2021

Castleman disease – Nature Reviews Disease Primers

Castleman disease includes several lymphoproliferative disorders with shared histopathological features but very different clinical presentations and course depending on the location and numbers of affected…

Dr Taryn Youngstein November 26, 2021

Covid-19 vaccines: patients left confused over rollout of third primary doses – The BMJ

“How a society treats its most vulnerable is always the measure of its humanity” is a well-known quote often attributed to Mahatma Gandhi. With the…

Dr Taryn Youngstein November 24, 2021

UK threw away 600,000 vaccine doses after they passed expiry date

Exclusive: AstraZeneca shots were destroyed in August following a change in vaccination policy

Dr Taryn Youngstein November 16, 2021

VROOM home page | VROOM

Welcome to the VROOM study website! Full study title: A multi-centre randomised controlled trial examining the effects of temporarily suspending low-dose methotrexate treatment for two…

Dr Taryn Youngstein November 12, 2021

Related Articles